Exenatide

Exenatide was the first GLP-1 receptor agonist to reach the market, and its origin story is genuinely odd: the molecule is a synthetic version of exendin-4, found in the saliva of the Gila monster, a venomous lizard native to the American Southwest. It resembles human GLP-1 closely enough to activate the same receptor, but differently enough to resist the enzyme that destroys the natural hormone within minutes.

Two formulations exist. Byetta is the twice-daily version; its label directs injection within the 60-minute window before the morning and evening meals, starting at 5 mcg per dose and increasing to 10 mcg twice daily after a month based on response. Bydureon was the once-weekly extended-release version. Both are indicated for glycemic control in adults with type 2 diabetes — neither is approved for weight management.

The mealtime timing is the tell. A short-acting GLP-1 blunts the glucose spike from the meal you are about to eat, which is a narrower job than the continuous receptor coverage a weekly drug provides. That difference plausibly explains why exenatide did not reproduce the cardiovascular benefit seen with longer-acting agents.

EXSCEL tested once-weekly exenatide in 14,752 adults and found the primary cardiovascular composite occurred in 11.4% versus 12.2% on placebo — noninferior, not superior. The safety data were reassuring: no significant differences in acute pancreatitis, pancreatic cancer or medullary thyroid carcinoma versus placebo. Exenatide is also the drug behind the small Parkinson’s disease research line, which remains investigational.

Worth asking your clinician: whether an older GLP-1 is being suggested because of cost or coverage rather than efficacy, and whether a twice-daily mealtime injection fits your life. Our EXSCEL deep dive and cardiovascular study roundup place it against the newer agents.